NCT00993486View on ClinicalTrials.gov

Dose-ranging Study of a Single Administration of T-cell Add-back Depleted of Host Alloreactive Cells in Patients Undergoing a Peripheral Blood Stem Cell Transplant From a Related, Haploidentical Donor

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

19

Participants

Timeline

Start Date

January 31, 2005

Primary Completion Date

October 31, 2008

Study Completion Date

April 30, 2013

Conditions
Hematologic DiseasesHematologic Malignancies
Interventions
BIOLOGICAL

Donor lymphocyte preparation depleted of functional host alloreactive T-cells (ATIR)

Single intravenous infusion

Trial Locations (1)

H1T 2M4

Maisonneuve-Rosemont Hospital, Montreal

Sponsors

Lead Sponsor

Kiadis Pharma
All Listed Sponsors
lead

Kiadis Pharma

INDUSTRY

NCT00993486 - Dose-ranging Study of a Single Administration of T-cell Add-back Depleted of Host Alloreactive Cells in Patients Undergoing a Peripheral Blood Stem Cell Transplant From a Related, Haploidentical Donor | Biotech Hunter | Biotech Hunter